Trials / Completed
CompletedNCT00524810
Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer
A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer
Detailed description
Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated liposomal doxorubicin | Caelyx 30 mg/m² day 1 every 3 weeks |
| DRUG | Docetaxel | Taxotere 75 mg/m² day 2 every 3 weeks |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2009-06-01
- Completion
- 2009-06-01
- First posted
- 2007-09-05
- Last updated
- 2011-06-30
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00524810. Inclusion in this directory is not an endorsement.